{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
Broperamole by Onbio Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Broperamole has been studied as an anti-inflammatory agent.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (RACEMIC)
Rimiterol is erythro-(3,4-dihydroxyphenyl)-2-piperidyl-methanol hydrobromide, and is a catecholamine. It is a selective β2-adrenoreceptor agonist, but is not effective as a bronchodilator by the oral route of administration. Rimiterol is available at present as an aerosol, though preliminary studies suggest that it may be of value in the intravenous therapy of severe asthma.
Status:
Possibly Marketed Outside US
Source:
Butadiazamide by Onbio Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Butadiazamide is an oral hypoglycemic.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Bamifylline (or bamiphylline), a selective antagonist of the A1 adenosine receptor, was studied in the therapy of asthmatic syndromes.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Tiazofurin (NSC-286193; 2-beta-D-ribofuranosylthiazole-4-carboxamide) an approved chronic myeloid leukemia (CML) drug, is converted by cellular enzymes into tiazofurin adenine dinucleotide, TAD, which inhibits the enzyme as a cofactor mimic. Resistance to tiazofurin is quickly developed due to diminished ability of resistant cells to synthesize TAD and increased enzymatic degradation of TAD. It is a nucleoside analog with oncolytic activity being developed by Ribapharm (formerly ICN Pharmaceuticals) as a potential treatment for leukemia. Ribapharm, through a Russian subsidiary of ICN, is planned to conduct phase II studies of tiazofurine involving patients suffering from advanced ovarian cancer or multiple myeloma which is resistant to conventional therapy.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Lormetazepam (or methyl-lorazepam), possesses hypnotic, anxiolytic, sedative and skeletal muscle relaxant properties. Lormetazepam is not approved for sale in the United States or Canada, though it is licensed in the Netherlands as 1 and 2 mg tablets, under the brand names Loramet and Noctamid and as generic, available from several different manufacturers. Lormetazepam is a short-acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep or falling asleep. Lormetazepam binds to the benzodiazepine receptor which in turn enhances the effect of the GABAA receptor producing its therapeutic effects as well as adverse effects. Lormetazepam appears to be more selective in the type of benzodiazepine receptor it binds to showing a higher affinity for the omega 1 receptor which is responsible for sedation. Changes in electroencephalography can therefore be used to measure the sedative sleep promoting properties of lormetazepam.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Gemeprost is a PGE1 analogue indicated for softening and dilatation of the cervix uteri prior to operative procedures or therapeutic abortion. The drug is marketed under the name Cervagem.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Cibenzoline is a class I sodium channel blocker
antiarrhythmic drug available in a limited number
of countries. Cibenzoline also has moderate calcium channel blocking (class IV) effects and prolongs the action potential duration through its potassium channel blocking (class III) effect. It is used for the treatment of supraventricular and ventricular arrhythmias, and in obstructive hypertrophic cardiomyopathy.
Status:
Possibly Marketed Outside US
Source:
Palerol by Novartis
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Piperylone is a non-narcotic analgesic and antispasmodic agent.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Gefarnate is a drug used for the treatment of gastric ulcers. It also has been proposed for use in the treatment of dry eye syndrome, although for this disease it was discontinued in 2008. The mechanism of action consists of the normalisation of the mucous secretion, followed by the restoration of the normal defensive mucous barrier.